The pharmaceutical Latanoprost EQL Pharma, eye drops 50 micrograms/ml, has been approved for sale in Sweden, Denmark and Norway. Latanoprost EQL Pharma is by prescription-only and is used in the treatment of glaucoma in children and adults. It works by lowering the increased pressure that this disease causes in the eye. Latanoprost EQL Pharma has a planned launch date in the company's first financial quarter (April-June) next year. The Scandinavian market for Latanoprost currently has sales of approximately SEK 50 million and has between two and five active competitors per country.